ChartMill is a comprehensive online stock research platform designed to empower traders and investors with advanced tools for technical and fundamental analysis. The company provides a robust stock screener that allows users to filter thousands of stocks across major exchanges like NYSE, NASDAQ, and EURONEXT, using over 180 customizable technical and fundamental parameters to identify trading opportunities.
Sangamo Therapeutics (SGMO) reported Q2 2025 results with revenue missing estimates at $18.31M but a narrower loss of $0.08/share. Shares fell 9% post-earnings despite positive Fabry disease trial progress.
Atlassian Q4 2025 earnings beat revenue and EPS estimates with $1.38B sales and $0.98 EPS, but stock dipped 2% amid GAAP losses and cautious AI monetization outlook.
Wynn Resorts reported mixed Q2 2025 results, missing revenue and EPS estimates but showing resilience in Las Vegas and Macau operations. Shares fell 3% post-earnings.
Celldex Therapeutics Q2 2025 earnings: Revenue misses estimates at $730K, but EPS beats at -$0.85. Strong cash position supports pipeline, with key barzolvolimab trials progressing.
Astrana Health reports mixed Q2 2025 earnings with revenue beating estimates but EPS missing by 49%. Stock surges 10.4% in after-hours trading despite broader concerns.
Microchip Technology reports mixed Q1 FY2026 results with revenue in line but EPS beating estimates. Shares drop 6% amid year-over-year revenue decline. Dividend announced at $0.455 per share.
Pinterest's Q2 2025 earnings show 17% revenue growth to $998M but miss EPS estimates, causing a 13% stock drop. User growth remains strong, but higher costs impact profitability.
Integral Ad Science (IAS) beat Q2 2025 earnings with $149.2M revenue (+16% YoY) and $0.07 EPS, driving a 4.3% stock surge. Strong ad verification growth boosts investor confidence.
10X Genomics (TXG) reported strong Q2 2025 earnings, beating revenue and EPS estimates, sparking a 4.68% after-hours stock surge. Revenue hit $172.91M, up 22.8%, with EPS at $0.28 vs. expected loss. Growth driven by Chromium & Visium platforms.
Expedia Group beats Q2 estimates with strong revenue and EPS growth, raises full-year guidance, sparking a 13.7% stock surge. B2B and advertising segments shine.
CytomX Therapeutics (CTMX) Q2 2025 revenue beat estimates at $18.66M, with break-even EPS. Shares rose slightly as clinical progress, including CX-2051 data, boosts optimism.
Expensify Inc. (EXFY) reported Q2 2025 revenue growth of 7% to $35.8M but posted a wider-than-expected loss of -$0.10 EPS. Shares fell 7.2% amid investor concerns despite FCF growth and UK/EU card expansion.
Corvus Pharmaceuticals reported a narrower Q2 2025 loss of $0.10 per share, beating estimates, with shares rising 5.8% after-hours. Positive Phase 1 data for soquelitinib in atopic dermatitis boosted investor optimism.
APYX Medical Corp reported Q2 2025 results with revenue of $11.37M, missing estimates, but a narrower EPS loss of -$0.09. Stock shows muted reaction amid commercial expansion plans.
Dianthus Therapeutics Q2 2025 earnings show revenue miss but EPS in line. Cash reserves strong, key clinical trials progressing with major data readouts expected in 2025-2026.
Texas Roadhouse Q2 2025 earnings missed revenue and EPS estimates, triggering a 2.7% stock drop. Dividend maintained at $0.68/share. Analysts provide Q3 and full-year forecasts.
PTC Therapeutics (PTCT) reported strong Q2 2025 earnings, beating revenue estimates at $179M and narrowing EPS loss. Growth driven by Sephience™ launch for PKU in U.S. & Europe. Stock up 5.4% in a month.
AudioEye Inc. reports mixed Q2 2025 results with record revenue but misses estimates, sparking a 10% stock drop. EPS beats forecasts, but revenue shortfall drives negative market reaction.
MicroVision (MVIS) Q2 2025 earnings missed revenue estimates but slightly beat EPS expectations. Revenue fell short at $0.2M, while net loss narrowed to $0.06/share. Stock dipped 3.58% post-report. Key updates include NVIDIA integration and defense sector progress.
CytoSorbents (CTSO) reported Q2 2025 results with revenue of $9.62M, beating estimates, and a narrower EPS loss of -$0.05. Shares rose 4.32% post-earnings amid steady demand for CytoSorb.
Let's delve into the developments on the US markets one hour before the close of the markets on Thursday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Get a pulse on the US markets on Thursday by checking out the most active stocks in today's session. Discover the stocks that are leading the way in terms of trading volume and market activity.
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session.
Wondering how the US markets performed in the middle of the day on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.
Thursday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session.
SAGA Communications (SGA) missed Q2 2025 earnings and revenue estimates, with a 5% revenue decline and lower EPS. Political ad weakness drove the drop, but cost cuts and dividends offer stability. Stock fell -3.8%.
PepGen reported a Q2 2025 net loss of $23.1M, beating EPS estimates. Clinical progress in DM1 trials and stable cash position highlight the update. Stock shows mixed performance amid legal scrutiny.
Marcus & Millichap's Q2 2025 results show revenue up 8.8% to $172.3M but a wider net loss of $11.0M amid commercial real estate volatility. Stock rose slightly post-earnings.
Oxford Square Capital (OXSQ) reported Q2 2025 results with revenue of $9.52M, missing estimates, and EPS of $0.08, slightly below forecasts. Stock reaction remains muted.
GCM Grosvenor's Q2 2025 earnings met expectations with $119.66M revenue and $0.16 EPS. Strong fundraising growth and profitability gains noted, but market reaction remains neutral.
Sempra's Q2 2025 earnings met EPS estimates at $0.89 but revenue missed at $3.0B. GAAP earnings fell, while adjusted earnings stayed flat. Stock dipped slightly pre-market but gained 9% over the past month.
MarketWise Inc (MKTW) reported Q2 2025 results with revenue beating estimates at $80M but EPS missing at $0.53. Stock rose 9.98% pre-market on strong cash flow and dividend news. Full-year outlook remains positive.
